Literature DB >> 10375390

Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.

C M Gibson1, J L Moynihan, E N Al-Mousa, M Campsey, R Gandhi, S Murphy, S Mattson, K A Ryan, R Mesley, J Swanson, M N Arshad, S J Marble.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10375390     DOI： 10.1023/a:1008935227780

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  37 in total

1.  Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.

Authors:  E J Topol; J J Ferguson; H F Weisman; J E Tcheng; S G Ellis; N S Kleiman; R J Ivanhoe; A L Wang; D P Miller; K M Anderson; R M Califf
Journal:  JAMA       Date:  1997-08-13       Impact factor: 56.272

2.  Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy.

Authors:  Y F Zhou; M B Leon; M A Waclawiw; J J Popma; Z X Yu; T Finkel; S E Epstein
Journal:  N Engl J Med       Date:  1996-08-29       Impact factor: 91.245

3.  Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men.

Authors:  T H Müller; H Weisenberger; R Brickl; H Narjes; F Himmelsbach; J Krause
Journal:  Circulation       Date:  1997-08-19       Impact factor: 29.690

4.  Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.

Authors:  C P Cannon; C H McCabe; S Borzak; T D Henry; M D Tischler; H S Mueller; R Feldman; S T Palmeri; K Ault; S A Hamilton; J M Rothman; W F Novotny; E Braunwald
Journal:  Circulation       Date:  1998-02-03       Impact factor: 29.690

5.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.

Authors: 
Journal:  N Engl J Med       Date:  1997-06-12       Impact factor: 91.245

6.  Meeting highlights.

Authors:  J J Ferguson
Journal:  Circulation       Date:  1995-06-15       Impact factor: 29.690

7.  Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms.

Authors:  R M Scarborough; J W Rose; M A Naughton; D R Phillips; L Nannizzi; A Arfsten; A M Campbell; I F Charo
Journal:  J Biol Chem       Date:  1993-01-15       Impact factor: 5.157

Review 8.  The pharmacology of the integrins.

Authors:  D Cox; T Aoki; J Seki; Y Motoyama; K Yoshida
Journal:  Med Res Rev       Date:  1994-03       Impact factor: 12.944

9.  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.

Authors: 
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

10.  Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

Authors:  S J Brener; L A Barr; J E Burchenal; S Katz; B S George; A A Jones; E D Cohen; P C Gainey; H J White; H B Cheek; J W Moses; D J Moliterno; M B Effron; E J Topol
Journal:  Circulation       Date:  1998-08-25       Impact factor: 29.690
View more
  1 in total

Review 1.  Monitoring antiplatelet therapy: What is the best method?

Authors:  D Mukherjee; D J Moliterno
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.